Abstract
Introduction
HCC is a common malignant tumor especially in East Asia, resulting in more than 250,000 deaths each year in China (1) (2) (3) . In spite of enormous efforts to improve clinical treatment, the overall survival of patients with HCC remains unsatisfactory because of a high incidence of recurrence and metastasis. Recent research efforts on stem cells have shed light on new directions for the eradication of cancer stem cells (CSCs) in HCC (4) (5) (6) . This crucial early role for epigenetic alterations in cancer is in addition to epigenetic alterations that can substitute for genetic variation later in tumour progression (7) . Numerous recent findings in the molecular biology of cancer suggest that the neoplasticphenotype arises and is maintained through genome-wide modifications associated with epigenetic changes (8) (9) . BORIS is an unique epigenetically acting, tumor-promoting, transcription factor expressed in different types of human and mouse cancer cells has been recently described (10) .
BORIS gene was first described as a DNA-binding protein that shares 11 zinc finger (ZF) domains with CCTC-binding factor (CTCF), but differs from this molecule at the N and C Termini (11) . Lobanenkov etal originally identified the CCCTC-binding factor (CTCF) as a transcription factor regulating cmyc expression (12, 13) , which was subsequently found to act as a tumor suppressor (14) (15) (16) . BORIS as the same protein family with CTCF have arosen increasing attention since its decreasing methylation of DNA. BORIS protein is absent in nonmalignant male tissues with the exception of testis, and is totally absent in females. However, BORIS transcripts were detected in more than half of the cancer cell lines (10) . Several collaborating laboratories have initiated studies of BORIS expression in a variety of primary cancers (17, 18) . supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37 with 5% CO 2 .
Immunohistochemical and Histochemical Double Staining
The embedded tissues were cut into 4-um-thick sections for histologicalstudies by hematoxylin-eosin staining. BORIS protein was detected with a specific rabbit on the same sections using Envision Doublestain System (DAKO, Glostrup, Denmark). Deparaffinization and antigen retrieval were performed as described above.
After quenching the endogenous peroxidase activity with peroxidase blocking reagent (DAKO, Glostrup, Denmark), tissue sections were incubated with mouse monoclonal anti-CD90 antibodies for one hour at room temperature, followed by rinsing with washing buffer. Then the tissue sections were subjected to the second staining for BORIS with the sequential steps of quenching the, incubation with anti-BORIS antibodies, incubation with anti-goat IgG antibodies and detection of the phosphatase activity in accordance with the manufacturer's instructions (Envision Doublestain System, DAKO, Glostrup, Denmark).
Immunofluorescence detection of BORIS and CD90 derived from liver cancer tissues frozen section. Antibodies were conjugated to Alexa Fluorescent dyes (Invitrogen).
Fluorescent images were acquired at 2-mm Z-axis intervals using a confocal microscope (Leica TCS SP5 II)
Immunohistochemical staining and assessment of BORIS levels in HCC and paracancer tissues
Immunohistochemical analysis was done by staining normal (n=20), cirrhosis (n=16), paracancer tissues (n=34), HCC (n=58) with the Vectastain Elite ABC standard kit (Vector Laboratories, Burlingame, CA) as suggested by the manufacturer.
Immunohistochemical staining was evaluated by using the immunoreactivity score (IRS) as previously described (19) . In brief, the percentage of BORIS-positive cells was divided into four categories (<10%, 11-50%,51-80%, and >80%, with corresponding scores of 1, 2, 3, and 4, respectively), whereas the staining intensity was given a value between 0 (no detectable immunostaining) and 3 (strong immunostaining). The IRS (0-12) was then calculated by multiplying the score values.
Scoring was done in a blinded fashion by two independent scorers, with each slide read twice.
Reverse transcription-PCR
To determine the BORIS transcription in human HCC cell lines, total RNA was 
Statistical analysis
Data were expressed as (mean ± standard deviation) or median with range.
SPSSprogram for Windows (version 15.0, SPSS Inc, USA) was used for statistical analysis.Comparisons of BORIS tumor expression with clinical and pathologic features were evaluated by using chi-square tests. Overall survival analyses were estimated by using the Kaplan-Meier method. The student's t-test was used to detect differences between groups. All tests performed were two-tailed. A difference was considered significant if p<0.05. Immunofluorescence.
Results

BORIS expression in hepatoculluar carcinoma cell lines
BORIS expression was investigated in different human
Prognostic significance of BORIS expression
To elucidate the prognostic role of BORIS in HCC, overall survival rates were estimated by Kaplan-Meier survival curves (Figure4). the expression of BORIS was associated with the poor prognosis of patients with HCC (P = 0.003, log-rank test). In the present study, we investigated the BORIS mRNA and protein expression in HCC cell lines or primary HCC tissue , and evaluated the correlation of BORIS expression and clinical outcome of HCC patients in HCC tissue study, we found that BORIS expression of HCC tissue was obviously higher than that in normal tissue, which suggests that BORIS may be involved in the genesis and development of liver cancer, and it might be used in clinical practice as an indicator of liver cancer.
On the other hand, we further found BORIS expression in different human liver cell lines, which suggests that BORIS is likely to be associated with malignant liver cells.
In the present study, our results showed that BORIS was very frequently expressed in HCC as compared to no cancerous tissue. We obtained more informative results probably because of the larger number of cases examined by IHC analysis. We found that the expression of BORIS is also correlated with high proliferating activity and poor overall survival rate. Our study also
showed that the expression of BORIS in HCC is significantly related to cancer stem More ever, the expression of BORIS also showed a tendency to correlate with high tumor metastasis rate in the liver (Table1).The present study made it clearer that BORIS strongly reflects the biological aggressiveness of this carcinoma and plays an important role in its progression. These results also suggested that the HCC patients with BORIS expression very probably have a relapse and have poor prognosis, and BORIS may become a newly useful prognostic indicator for the HCC. Thus, inhibiting BORIS activity might contribute to the application of adjuvant therapy intervention for HCC.
In summary, our study has shown for the first time that BORIS is expressed in HCC tissues and its expression significantly correlates with a poor prognosis of HCC.
Furthermore, we demonstrated The expression of cancer stem cell marker CD90 is related to the expression of BORIS in HCC tissue and hepatocellular Carcinoma cell lines the expression of BORIS in stem cell could provide experimental basis and theory evidence for treating liver cancer taking BORIS as target point.
